Research Article | DOI: https://doi.org/10.31579/2835-9232/041
Pharmacotherapy For Obsessive-Compulsive Disorder: An Educational Article
- Aamir Al-Mosawi *
Advisor doctor and expert trainer, The National Center of Training and Development Iraqi Ministry of Health, Baghdad, Iraq.
*Corresponding Author: Aamir Al-Mosawi, Advisor doctor and expert trainer, The National Center of Training and Development Iraqi Ministry of Health, Baghdad, Iraq.
Citation: Aamir Al-Mosawi, (2023), Pharmacotherapy for obsessive-compulsive disorder: An educational article. J, International journal of clinical epidemiology, 2(5); Doi: 10.31579/2835-9232/041
Copyright: © 2023, Aamir Al-Mosawi. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: 28 September 2023 | Accepted: 10 October 2023 | Published: 19 October 2023
Keywords: trypanosomiasis; philately; postage stamps; blocks; envelopes; medals; coins
Abstract
Background: Various medications have been used in the treatment of obsessive-compulsive disorder during the 1960s including imipramine (A tricyclic antidepressant), benzodiazepines including oxazepam, and lithium. However, clomipramine has been increasingly used during the 1970s. (A tricyclic antidepressant). However, more than 20% of patients with obsessive-compulsive disorder continue to represent a therapeutic challenge for the treating physicians. Selective serotonin reuptake inhibitors have become an integral part of pharmacotherapies for obsessive-compulsive disorder, and the addition of low dose neuroleptic has been increasingly suggested when treating difficult cases.
Patients and methods: The case of a 24-year-old female with obsessive compulsive disorder who didn’t respond to several medication is presented, and the evidence-based therapeutic approach to such case is discussed.
Results: The patient started experiencing the obsessions before about few months during the year 2023, and the obsessions resulted in excessive cleaning as the main compulsion. The illness was complicated with symptoms of anxiety and depression. The patient was treated with multiple medications for only short periods because of intolerance and the development of a variety of unwanted side effects including headaches and tremor. Medications included oral deanxit (Flupentixol plus melitracen), oral olanzapine, oral clonazepam, imipramine (Tofranil), oral paroxetine, oral Escitalopram, oral levetiracetam.
Therefore, the patient was treated according to the available evidence with oral citalopram 20 mg daily plus oral risperidone in an initial dose of 1 mg at night, to be gradually increasing to 2 mg depending on the occurrence of excessive drowsiness. Ondansetron was also given in an initial dose of 4 mg daily in the morning, to be gradually increasing to 8 mg based depending on the occurrence of unwanted gastrointestinal symptoms. Celecoxib was given in an initial dose of 200 mg daily in the morning with possible increase in dose if necessary.
Conclusion: The current evidence-based expert opinion suggests that difficult cases of obsessive-compulsive disorder that are commonly associated with medication intolerance can be treated with relatively low doses of citalopram plus risperidone plus ondansetron plus Celecoxib. If adequate response is not obtained, lamotrigine can be added with gradually withdrawing ondansetron and Celecoxib.
Introduction
obsessive compulsive disorder is a psychiatric condition that impairs the quality of life because of its association with obsessions (Persistent irresistible unwanted thoughts such as fear of contamination) that produce compulsions (Desire to perform certain routines such as excessive hand washing and cleaning repeatedly) to alleviate anxiety, disgust or the distress resulting from the obsessions.
The disorder was mentioned in the medical literature as early as the 1800s.In the 1838, Jean Etienne Dominique Esquirol (Figure-1) described obsessive compulsive disorder in his psychiatric textbook and considered it to be as a type of monomania, or partial insanity.

Figure-1: Jean-Etienne Dominique Esquirol (3 February 1772 -12 December, 1840), a French psychiatrist
Various medications have been used in the treatment of this condition during the 1960s including imipramine (A tricyclic antidepressant), benzodiazepines including oxazepam, and lithium. However, clomipramine has been increasingly used during the 1970s. (A tricyclic antidepressant) [1-5].
Patients and methods
The case of a 24-year-old female with obsessive compulsive disorder who didn’t respond to several medication is presented and the evidence-based therapeutic approach to such case is discussed.
Results
The patient started experiencing the obsessions before about few months during the year 2023, and the obsessions resulted in excessive cleaning as the main compulsion.
The illness was complicated with symptoms of anxiety and depression. A part from recurrent headaches that received the diagnosis of migraine, the patient was considered otherwise healthy.
The patient was treated with multiple medications for only short periods because of medication intolerance and the development of a variety of unwanted side effects including headaches and tremor. Medications included oral deanxit (Flupentixol 0.5 mg plus melitracen 10 mg), oral olanzapine 3 mg, oral clonazepam 0.5mg, imipramine (Tofranil) 25 mg, oral paroxetine, oral Escitalopram (Cipralex) 20 mg, and oral levetiracetam (Keppra).
Therefore, the patient was treated with oral citalopram 20 mg daily based on the evidence provided by Thomsen (1997), Koponen et al (1997), Pallanti et al (1999), and Mukaddes and colleagues (2003) [6,7,8,9]. Citalopram was given at 1pm to avoid the possibility of excessive drowsiness or sedation in the morning or insomnia at night.
The patient was also given oral risperidone in an initial dose of 1 mg at night, to be gradually increasing to 2 mg depending on the occurrence of excessive drowsiness. The use of risperidone based on the evidence provided by Jacobsen (1995), Ravizza et al (1996), Saxena et al (1996), Salmerón and colleagues (1998), and McDougle et al (2000) [10-14].
Ondansetron was given in an initial dose of 4 mg daily in the morning, to be gradually increasing to 8 mg based depending on the occurrence of unwanted gastrointestinal symptoms. The use of ondansetron was based on the evidence provided by Al-Mosawi (2023) [15].
Celecoxib in an initial dose of 200 mg daily in the morning with possible increase in dose if necessary Sayyah et al (2011) [16].
Discussion
More than 20% of patients with obsessive-compulsive disorder continue to represent a therapeutic challenge for the treating physicians. Selective serotonin reuptake inhibitors have become an integral part of pharmacotherapies for obsessive-compulsive disorder, and the addition of low dose neuroleptic has been increasingly suggested when treating difficult cases.
Of the five serotonin reuptake inhibitors including citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline that were used for use in obsessive-compulsive disorder; Citalopram is most probably the selective serotonin reuptake inhibitors that is associated with least possibility of the occurrence of side effects. Risperidone seems to the neuroleptic that is most probably associated with least occurrence of side effects in a relatively low dose [6-14].
Many of the medications the patient received in this paper for the treatment of obsessive-compulsive disorder including flupentixol, melitracen, and levetiracetam were used without acceptable supporting scientific evidence. In fact, levetiracetam, an antiepileptic medication has been reported to be associated with several psychiatric adverse effects including obsessive compulsive behavior [17].
In 2003, Mukaddes and colleagues from Turkey reported a study which included 15 children and adolescence (9 males and 6 females) who had obsessive compulsive disorder, and treated with oral citalopram 20-30 mg/day for eight weeks. Treatment was associated with improvement in 14 patients. Side effects occurred during the first week and included sedation in one patient and insomnia in one patient [9].
The use of lamotrigine to enhance the therapeutic response to serotonin re-uptake inhibitors and clomipramine in difficult cases obsessive-compulsive disorder has been increasingly reported [18, 19, 20, 21].
In 2012, Antonio Bruno from Italy and his research group reported a16-week placebo-controlled study which showed that the addition of oral lamotrigine 100 mg daily to serotonin reuptake inhibitors used for treating obsessive-compulsive disorder can significantly improve the therapeutic response. According to Antonio Bruno from Italy and his research group the addition of lamotrigine was well tolerated [20].
Conclusion
The current evidence-based expert opinion suggests that difficult cases of obsessive-compulsive disorder that are commonly associated with medication intolerance can be treated with relatively low doses of citalopram plus risperidone plus ondansetron plus Celecoxib. If adequate response is not obtained, lamotrigine can be added with gradually withdrawing ondansetron and Celecoxib.
Acknowledgement
The figure included in this paper was included in the author’s previous publication, but the author has its copyright.
Conflict of interest
None.
References
- Esquirol Étienne. Baillière, Jean-Baptiste (and sons) (Ed.). (1838). Des maladies mentals considered sous les rapports médical, hygiénique et médico-légal, Volume 1 [Mental illness as considered in medical, hygienic, and medico-legal reports, Volume 1] [In French]
View at Publisher | View at Google Scholar - Ciani N, Silipo P. (1964). Prime osservazioni sull'associazione dell'imipramina e della butirrilperazina nel trattamento delle psiconevrosi ossessivo-fobiche [First observations on the association of imipramine and butyrrilperazine in the treatment of obsessive-phobic psychoneuroses]. Gazz Int Med Chir 31; 68(24).
View at Publisher | View at Google Scholar - Orvin GH. (1967). Treatment of the phobic obsessive-compulsive patient with oxazepam, an improved benzodiazepine compound. Psychosomatics. 8(5):278-80.
View at Publisher | View at Google Scholar - Geisler A, Schou M. Lithium ved tvangsneuroser. (1969). En dobbelt-blind terapeutisk undersøgelse [Lithium for obsessive-compulsive neuroses. A double-blind therapeutic trial]. Nord Psykiatr Tidsskr; 23(5):493-5.
View at Publisher | View at Google Scholar - Amin MM, Ban TA, Pecknold JC, Klingner A. (1977). Clomipramine (Anafranil) and behaviour therapy in obsessive-compulsive and phobic disorders. J IntMed Res.; 55:33-7.
View at Publisher | View at Google Scholar - Karabanow O. (1977). Double-blind controlled study in phobias and obsessions. J Int Med Res; 5 Suppl 5:42-8.
View at Publisher | View at Google Scholar - Thomsen PH. (1997). Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial of 23 cases. J Child Adolesc Psychopharmacology 1997; 7(3):157-66.
View at Publisher | View at Google Scholar - Koponen H, Lepola U, Leinonen E, Jokinen R, Penttinen J, Turtonen J. (1997). Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study. Acta Psychiatr Scand Nov; 96(5):343-6.
View at Publisher | View at Google Scholar - Pallanti S, Quercioli L, Paiva RS, Koran LM. (1999). Citalopram for treatment-resistant obsessive-compulsive disorder. Eur Psychiatry 14(2):101-6.
View at Publisher | View at Google Scholar - Mukaddes NM, Abali O, Kaynak N. (2003). Citalopram treatment of children and adolescents with obsessive-compulsive disorder: a preliminary report. Psychiatry Clin Neurosci 57(4):405-8.
View at Publisher | View at Google Scholar - Jacobsen FM. (1995). Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry 56(9):423-9.
View at Publisher | View at Google Scholar - Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. (1996) Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol Bull; 32(4):677-82.
View at Publisher | View at Google Scholar - Saxena S, Wang D, Bystritsky A, Baxter LR Jr. (1996) Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 57(7):303-6:8666572.
View at Publisher | View at Google Scholar - Salmerón JM, Alcántara AG, Barcia D. (1998). Combinación de risperidona y antidepresivos serotoninérgicos en el trastorno obsesivo compulsivo refractario [Combination of risperidone and serotonergic antidepressants in refractory obsessive-compulsive disorder]. Actas Luso Esp Neurol Psiquiatr Cienc Afines Nov-Dec; 26(6):399-402.
View at Publisher | View at Google Scholar - McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. (2000). A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 57(8):794-801.
View at Publisher | View at Google Scholar - Al-Mosawi AJ. (2023). The use of ondansetron in psychiatry: An educational article and expert opinion. Journal of Drug Delivery and Therapeutics (ISSN: 2250-1177) -08-15; 3(8):1-2.
View at Publisher | View at Google Scholar - Sayyah M, Boostani H, Pakseresht S, Malayeri A. A preliminary randomized double-blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive-compulsive disorder. Psychiatry Res 2011 Oct 30; 189(3):403-6.
View at Publisher | View at Google Scholar - Fujikawa M, Kishimoto Y, Kakisaka Y, Jin K, Kato K, Iwasaki M, Nakasato N. (2015). Obsessive-compulsive behavior induced by levetiracetam. J Child Neurol 30(7):942-4.
View at Publisher | View at Google Scholar - Kumar TC, Khanna S. (2000). Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder. Aust N Z J Psychiatry 34(3):527-8.
View at Publisher | View at Google Scholar - Uzun O. (2010) Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: a case report. J Psychopharmacology 24(3):425-7
View at Publisher | View at Google Scholar - Bruno A, Micò U, Pandolfo G, Mallamace D, Abenavoli E, Di Nardo F, D'Arrigo C, Spina E, Zoccali RA, Muscatello MR. (2012) Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Psychopharmacol 26(11):1456-62.
View at Publisher | View at Google Scholar - Arrojo-Romero M, Tajes Alonso M, de Leon J. (2013). Lamotrigine augmentation of serotonin reuptake inhibitors in severe and long-term treatment-resistant obsessive-compulsive disorder. Case Rep Psychiatry; 2013:612459.
View at Publisher | View at Google Scholar